Quick Answer
Pyxis Oncology, Inc. reported Stockholders Equity of $53.41 million for fiscal year 2025.
Pyxis Oncology, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $53.41M | -55.8% |
| 2024 | $120.75M | -3.9% |
| 2023 | $125.70M | -21.8% |
| 2022 | $160.82M | -38.5% |
| 2021 | $261.31M | +1770.3% |
| 2020 | -$15.64M | -444.4% |
| 2019 | -$2.87M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $68.78M | -55.2% | -21.5% |
| June 30, 2025 | $87.64M | -48.4% | -15.0% |
| March 31, 2025 | $103.10M | -44.0% | -14.6% |
| December 31, 2024 | $120.75M | -3.9% | -21.4% |
| September 30, 2024 | $153.68M | +11.4% | -9.5% |
| June 30, 2024 | $169.79M | +16.9% | -7.8% |
| March 31, 2024 | $184.16M | +21.0% | +46.5% |
| December 31, 2023 | $125.70M | -21.8% | -8.9% |
- Pyxis Oncology, Inc. showed a decrease of -55.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Pyxis Oncology, Inc.’s stockholders equity has grown by 1958.3% (from -$2.87 million to $53.41 million).
- The most recent figure is from Pyxis Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: